SYNM encodes synemin, a type VI intermediate filament protein that serves critical cytoskeletal functions in muscle cells 1. Synemin copolymerizes with desmin and vimentin intermediate filaments and interacts with cytoskeletal proteins including vinculin, α-actinin, α-dystrobrevin, dystrophin, talin, and zyxin, enabling linkage of intermediate filaments to adherens junctions at costameres, neuromuscular junctions, and myotendinous junctions 1. Functionally, synemin acts as an A-kinase-anchoring protein (AKAP) that anchors protein kinase A and modulates PKA-dependent phosphorylation of cytoskeletal substrates such as desmin 1. In smooth muscle cells, SYNM is transcriptionally regulated by myocardin and myocardin-related transcription factors in an SRF-independent manner 2. Pathologically, mutations in SYNM have been associated with cardiomyopathies and skeletal myopathies 134, with reported variants including missense mutations affecting protein structure 3. In cancer, SYNM promoter methylation occurs in 27% of breast cancers and associates with aggressive phenotypes, reduced expression, and early tumor relapse 5. Additionally, plasma SYNM levels show association with glioblastoma recurrence 6, and SYNM was identified as a potential diagnostic biomarker in prostate cancer and benign prostatic hyperplasia 7.